Inhaled stem cells could repair lungs in COPD – first human trial begins

NCT ID NCT06986070

Recruiting now Disease control Sponsor: SMSbiotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-stage trial tests whether inhaling small mobile stem cells (SMS) is safe for people with mild to moderate COPD. 18 participants aged 39–69 will receive the cells via a nebulizer. The study focuses on safety and side effects, not yet on whether the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Small Mobile Stem Cells (SMS cells) inhaled via nebulizer
What this could lead to: If safe, this could pave the way for a new treatment that helps repair lung damage in COPD patients.
What could go wrong: This is a very early, first-in-human trial with only 18 people. The main goal is safety, not effectiveness. Stem cell treatments carry unknown risks, and the therapy may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE LUNG DISEASE

Contacts and locations

Locations

Doherty Clinical Trials Limited
RECRUITING

Melbourne, Victoria, 3002, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.